AM-101 in vitro treatment enhances the ATG12-ATG5 conjugate in both primary (H1792) and brain-metastatic (UW-lung-16) NSCLC cells (Figure 5B). The gene discussed is ATG5; the disease is non-small cell lung carcinoma.